Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 371

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 371
---
 through the sale of equity or convertible debt securities, the terms of these equity securities or this debt may restrict our ability to operate. Any future debt financing and equity financing, if available, may involve covenants limiting and restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, entering into profit-sharing or other arrangements or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise capital when needed or on acceptable terms, we could be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.

#### Cash Flows
Operating Activities

Our net cash used in operating activities was $1.3 million for the nine months ended September 30, 2024, as compared to $3.0 million for the nine months ended September 30, 2023. The decrease in cash used in operating activities can be attributed to a decrease in the Company’s net loss of $0.9 million, an increase in the Company’s amounts which are due to its research and development partner of $1.6 million which have yet to be paid, and an increase in accrued maintenance fees of $0.4 million, which have yet to be paid, offset by less advances to the Company for research and development of $1.2 million.

Our net cash used in operating activities was $3.3 million for the year ended December 31, 2023 as compared to $0.9 million for the year ended December 31, 2022. The increase in net cash used in operating activities of $2.4 million was primarily due to an increase in net loss of $2.1 million and $0.8 million of deferred transactions costs that were paid during the year ended December 31, 2023. The increase was partially offset by a decrease in advances for research and development, which were paid during the year ended December 31, 2022 and utilized during the year ended December 31, 2023, and increases in accounts payable and accrued expenses and due to related parties.

<div align='center'>202</div>

TABLE OF CONTENTS

Investing Activities

Net cash used in investing activities was $2.3 million for the nine months ended September 30,